$100 Invested In ResMed 10 Years Ago Would Be Worth This Much Today
ResMed (NYSE:RMD) has outperformed the market over the past 10 years by 7.12% on an annualized basis producing…
Earnings Scheduled For January 26, 2023
Companies Reporting Before The Bell
• Nokia (NYSE:NOK) is estimated to report quarterly earnings at $0.14 per share on revenue of $7.20 billion.
Benzinga’s Top Ratings Upgrades, Downgrades For January 17, 2023
Upgrades For Casa Systems Inc (NASDAQ:CASA), Northland Capital Markets upgraded the previous rating of Market Perform to Outperform.…
Keybanc Maintains Overweight on ResMed, Raises Price Target to $280
Keybanc analyst Matthew Mishan maintains ResMed (NYSE:RMD) with a Overweight and raises the price target from $276 to $280.
Earnings Scheduled For October 27, 2022
Companies Reporting Before The Bell
• Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million.
Hopeful Golden Cross Forms On ResMed’s Chart
If history is any guide, there may be good fortune ahead for shares of ResMed (NYSE:RMD). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.
Citigroup Upgrades ResMed to Buy
Citigroup analyst John Deakin-Bell upgrades ResMed (NYSE:RMD) from Neutral to Buy.
Competitor Recall Continues To Show Opportunities For ResMed
ResMed Inc (NYSE:RMD) posted Q4 sales of $914.7 million, +4% Y/Y (+8% on a constant currency basis), beating the consensus…
JP Morgan Downgrades ResMed to Neutral
JP Morgan analyst David Low downgrades ResMed (NYSE:RMD) from Overweight to Neutral.